Patents Examined by Susanna Moore
  • Patent number: 10695337
    Abstract: The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: June 30, 2020
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Taisheng Huang, Chu-Biao Xue
  • Patent number: 10689383
    Abstract: Disclosed are compounds of Formula I, which are active toward nuclear receptors such as nuclear retinoic acid receptor-related orphan receptors (RORs), pharmaceutical compositions containing the compounds of Formula I, and methods of treating inflammatory, metabolic, oncologic and autoimmune diseases or disorders using the of the compounds Formula I in therapy.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 23, 2020
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Kim Birkebæk Jensen, Niels Grøn Nørager, Ian Sarvary, Mikkel Vestergaard, Alex Haahr Gouliaev, Lene Teuber, Luigi Piero Stasi
  • Patent number: 10683290
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: June 16, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Claude A. Quesnelle, Lalgudi S. Harikrishnan, Matthew D. Hill
  • Patent number: 10683296
    Abstract: The present invention relates to a trifluoroacetate salt of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), crystalline form B of the trifluoroacetate salt, methods for preparing the trifluoroacetate salt and crystalline form B, and uses of the trifluoroacetate salt and crystalline form B.
    Type: Grant
    Filed: February 4, 2017
    Date of Patent: June 16, 2020
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaozhong Ding, Fei Sun, Yinghu Hu, Yilong Zhou, Zheng Wang, Rui Zhao, Ling Yang
  • Patent number: 10676446
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R12, R13, R14, A1, A2, A3, n and m are as described herein.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: June 9, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Christoph Kuratli, Rainer E. Martin, Patrizio Mattei, Alexander Lee Satz
  • Patent number: 10668090
    Abstract: Disclosed are a liver specific delivery (LSD)-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof, and in particular, provided are a compound of formula (I), and an isomer, a pharmaceutically acceptable salt, a hydrate and a solvate thereof, and the corresponding pharmaceutical composition. The present invention also provides uses of the present compounds, alone or in combination with other antiviral drugs, in the treatment of the diseases caused by hepatitis B virus (HBV), hepatitis D virus (HDV) and human immunodeficiency virus (HIV).
    Type: Grant
    Filed: December 22, 2018
    Date of Patent: June 2, 2020
    Assignee: ZHEJIANG PALO ALTO PHARMACEUTICALS, INC
    Inventors: Zhijian Xi, Huaqiang Xu, Chunping Lu, Zhongshan Wu, Feng Sun, Zhenwei Zhang
  • Patent number: 10669234
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer and conditions involving mitochondrial dysfunction. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: June 2, 2020
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Mark Kemp, Martin Stockley, Alison Jones
  • Patent number: 10669236
    Abstract: The present application provides solid Forms A, B, and C of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, and methods of preparing and using same. The compounds disclosed herein may be used in the treatment or prevention of a disease or condition in which a tyrosine kinase plays a role.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 2, 2020
    Assignee: Athenex HK Innovative Limited
    Inventor: Michael P. Smolinski
  • Patent number: 10654855
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: May 19, 2020
    Assignee: AstraZeneca AB
    Inventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
  • Patent number: 10640499
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: May 5, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Patent number: 10639310
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: May 5, 2020
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard
  • Patent number: 10640506
    Abstract: The present invention provides cyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I: wherein X, Y, Z, L, A, R5, n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: May 5, 2020
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Lixin Shao, Joseph Glenn
  • Patent number: 10618901
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: April 14, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Qian Liu, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Baowei Zhao, Colin Michael Edge
  • Patent number: 10610530
    Abstract: The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: April 7, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Hui-Yin Li, James D. Rodgers
  • Patent number: 10611767
    Abstract: Fused cyclic pyrimidine compounds, including tautomers thereof, and pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, are disclosed having the general Formula I: These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting GARFTase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: April 7, 2020
    Assignees: Duquesne University of the Holy Spirit, Wayne State University
    Inventors: Aleem Gangjee, Larry H. Matherly
  • Patent number: 10611764
    Abstract: The present invention relates to novel compounds which are aryl hydrocarbon receptor (AHR) ligands and uses thereof. Methods of activating the AHR receptor in a subject are also provided.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: April 7, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Yongna Xing, Seunghyeon Seok, Zhi-Xiong Ma, John Feltenberger
  • Patent number: 10604512
    Abstract: The present disclosure relates to indazole compounds having the following structure: or a pharmaceutically acceptable salt thereof, for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: March 31, 2020
    Assignee: Samumed, LLC
    Inventors: Sunil Kumar KC, David Mark Wallace, Jianguo Cao, Chandramouli Chiruta, John Hood
  • Patent number: 10604484
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 31, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Suchitra Ravula, Bradley M. Savall, Devin M. Swanson, Jeannie M. Ziff, Brock T. Shireman
  • Patent number: 10596174
    Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 24, 2020
    Assignee: ACEA THERAPEUTICS, INC.
    Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
  • Patent number: 10590116
    Abstract: Disclosed are 3-indolyl furanoid compounds which are useful as potent anti-inflammatory agents and prevent gastric ulcer by inhibiting matrix metalloproteinase-9 (MMP-9) expression in gastric mucosal layer. For example, disclosed is a compound of formula 1, wherein: R1 to R6 is selected from H, OH, CH3, OCH3, Br, Cl, Ph or o-OHC6H4, OCH2—CH?CH2, or OCH2CH2CH3, and R1 to R6 is having at least one substituent with alkyl, aryl and heteroaryl groups other than H, wherein the carbon in alkyl, aryl and heteroaryl is in the range of C1 to C8. Various embodiments relate to representative compounds of Formula 1 and method of preparation thereof. Further embodiments relates to the use of representative compounds of Formula 1 in treating diseases associated with gastric ulcer and other inflammatory diseases. A noted feature of an embodiment is the IC50 value of 50 ?M of one of the 3-indolyl furanoids.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: March 17, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Parasuraman Jaisankar, Snehasikta Swarnakar, Sourav Chatterjee, Sugreev Verma, Madhumita Mandal, Susri Ray Chaudhuri